On Tuesday, U.S. stocks floated lower, moving back from record levels reached during the earlier session, following the shareholders were vigilant ahead of another day of demonstration by Federal Reserve Chairwoman Janet Yellen.
Lackluster outcomes from Hewlett-Packard Inc. weighed on technology stocks, yesterday.
However, U.S. stocks opened Wednesday’s trade with a little change.
European stocks dropped down moderately. France’s CAC 40 dipped 0.1% and Germany’s DAX dropped down less than 0.1%. The U.K.’s FTSE 100 dipped 0.3%, pulling back from an all-time high.
On Wednesday, Ms. Yellen will be in hub once again. She gives evidence before the House Financial Services Committee at 10 a.m. EST.
The comprehensive details about few active gainers from technology sector, during the recent trade are illustrated as under:
Benefitfocus, Inc. (NASDAQ:BNFT), skyrocketed 52.50% and is now trading at $35.03, soon after Benefitfocus, stated Q4 EPS of ($0.39), $0.23 better than the analyst estimate of ($0.62). Proceed for the quarter came in at $40.2 million as compared to the consensus estimate of $38.5 million.
A leading provider of cloud-based benefits software solutions, formerly declared that Moffitt Cancer Center has selected BENEFITFOCUS® Marketplace to enhance its benefits administration. The software will be implemented collaboratively with one of Benefitfocus’ certified Systems Integrators, Providence Technology Solutions.
Located in Tampa, Fla., Moffitt has more than 4,500 employees and is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer since 1999.
We needed a benefits administration platform that could integrate with our systems and make our employees’ lives easier when it comes to benefits,” said Amy Durham, director of HR Operations for Moffitt. “Benefitfocus is dedicated to developing a science-driven, elegant design that will raise our efficiency in managing employee life events and ACA compliance.”
Benefitfocus, Inc. (NASDAQ:BNFT), is a leading provider of cloud-based benefits software solutions for consumers, employers, insurance carriers and brokers. Benefitfocus has served more than 23 million consumers on its platform that comprises of an integrated portfolio of products and services enabling clients to more efficiently shop, enroll, manage and exchange benefits information.
WaferGen Bio-systems, Inc. (NASDAQ:WGBS), inclined 25.18% and is now trading at $5.27, soon after a life science company that offers innovative genomic solutions for clinical testing and research, declared that it has produced positive results in a study aimed at validating the utility of its SmartChipTM technology for isolating and studying single cells via Next-Generation Sequencing (NGS). The study was conducted in partnership with the Broad Institute, and the findings will be presented at the 2015 Advances in Genome Biology & Technology (AGBT) meeting to be held February 25-28 in Marco Island, Florida.
In a proof of concept study, WaferGen has engineered a solution for depositing single cells into the individual SmartChipTM wells in a directed fashion, to achieve far greater chip utilization. At this level of efficiency, each chip could produce more than 4,000 single cells for analysis. The cell’s genetic composition was then successfully analyzed with the NGS method by adapting the Single Cell RNA Barcoding and Sequencing (SCRB-Seq) technology pioneered by the Broad Institute. SCRB-Seq measurements have already resulted in critical discoveries of novel cell types that play an important role in disease mechanisms.
“Single cell analysis has the potential to play a noteworthyrole in the development of precision medicine, which is transforming healthcare,” said Ivan Trifunovich, President and Chief Executive Officer of WaferGen. “We expect our SmartChipTM technology will be able to yield a 50-fold raise in the production of single cells per chip at a fraction of the current per cell cost. We continue to expect to launch an Early Access Program for this technology during the second quarter of 2015.”
WaferGen Bio-systems, Inc. (NASDAQ:WGBS), is a life science company that offers innovative genomic solutions for clinical testing and research. The SmartChip MyDesignTM Real-Time PCR System is a high-throughput genetic analysis platform for profiling and validating molecular biomarkers via microRNA and mRNA gene expression profiling, in addition to single nucleotide polymorphism (SNP) genotyping.
CollabRx, Inc. (NASDAQ:CLRX), jumped nearly 38.66%, and is now trading at $1.65, as a recognized leader in cloud-based expert systems to inform healthcare decision-making, declared the pricing of an underwritten public offering of 3,840,000 shares of its ordinary stock and warrants to purchase up to an aggregate of 3,840,000 shares of its ordinary stock at an offering price of $1.25 per ordinary share and $0.0001 per warrant. The warrants will have a per share exercise price of $1.56, are exercisable right away and will expire five years from the date of issuance. Gross proceeds to CollabRx from this offering are about $4,800,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by CollabRx. CollabRx has granted the underwriter a 45-day option to purchase up to an additional 576,000 shares of ordinary stock and/or 576,000 additional warrants to cover over-allotments, if any. The offering is predictable to close on February 25, 2015, subject to customary closing conditions.
Aegis Capital Corp. acted as the sole book-running manager for the offering.
CollabRx, Inc. (NASDAQ:CLRX), is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
Helios and Matheson Analytics Inc. (NASDAQ:HMNY), inclined 40.72% and is now trading at $4.93, soon after a 30 year old organization focused on the banking, financial services, insurance and healthcare sectors. Company provides a wide range of high quality information technology (“IT”) consulting solutions, custom application development and analytics services to Fortune 1000 companies and other large organizations. Company is providing the following preliminary (unaudited) information regarding the results of its operations for the fourth quarter of the year ended December 31, 2014: Proceed for the fourth quarter of 2014 is predictable to be about $2.4 million contrast to $3.3 million for the fourth quarter of 2013. Net revenue during the fourth quarter of 2014 is predictable to be $13,000 as contrast to $70,000 during Q4-2013. Proceed for the twelve months ended December 31, 2014 is predictable to be about $10.6 million as contrast to $13.3 million for the twelve months ended December 31, 2013, which is about a 20% decrease. Net Loss is predictable to be about ($178,000) or ($0.08) per basic and diluted share (EPS) for the twelve months ended December 31, 2014 as contrast to Net Revenue of $383,000 or $0.16 per basic and diluted share (EPS) for the twelve months ended December 31, 2013. During the year, the Company has made investments in furthering its analytics business.
Helios and Matheson Analytics Inc. is a 30 year old organization focused on the banking, financial services, insurance and healthcare sectors. It provides a wide range of high quality information technology (“IT”) consulting solutions, custom application development and analytics services to Fortune 1000 companies and other large organizations. Its ordinary stock is traded on the Nasdaq Global Market under the ticker symbol “HMNY”.
